Replimune Group Inc diskutieren
Replimune Group Inc
WKN: A2JQN1 / Symbol: REPL / Name: Replimune Group / Aktie / Small Cap /
?
0,00 %
Replimune Group, Inc. (NASDAQ: REPL) had its "overweight" rating re-affirmed by analysts at Piper Sandler. They now have a $44.00 price target on the stock.
Ratings data for REPL provided by MarketBeat
Replimune Group, Inc. (NASDAQ: REPL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $51.00 price target on the stock.
Ratings data for REPL provided by MarketBeat
Replimune Group, Inc. (NASDAQ: REPL) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $52.00 price target on the stock.
Ratings data for REPL provided by MarketBeat
Replimune Group, Inc. (NASDAQ: REPL) had its price target lowered by analysts at Barclays PLC from $50.00 to $13.00. They now have an "overweight" rating on the stock.
Ratings data for REPL provided by MarketBeat
Replimune Group, Inc. (NASDAQ: REPL) had its price target raised by analysts at HC Wainwright from $12.00 to $17.00. They now have a "buy" rating on the stock.
Ratings data for REPL provided by MarketBeat
Replimune Group, Inc. (NASDAQ: REPL) had its price target raised by analysts at Barclays PLC from $13.00 to $17.00. They now have an "overweight" rating on the stock.
Ratings data for REPL provided by MarketBeat
Replimune Group, Inc. (NASDAQ: REPL) had its price target lowered by analysts at JPMorgan Chase & Co. from $17.00 to $14.00. They now have an "overweight" rating on the stock.
Ratings data for REPL provided by MarketBeat
Replimune Group, Inc. (NASDAQ: REPL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock.
Ratings data for REPL provided by MarketBeat
Replimune Group, Inc. (NASDAQ: REPL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock.
Ratings data for REPL provided by MarketBeat
Replimune Group, Inc. (NASDAQ: REPL) had its price target raised by analysts at JPMorgan Chase & Co. from $14.00 to $17.00. They now have an "overweight" rating on the stock.
Ratings data for REPL provided by MarketBeat
Replimune Group, Inc. (NASDAQ: REPL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock.
Ratings data for REPL provided by MarketBeat
Replimune Group, Inc. (NASDAQ: REPL) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $17.00 price target on the stock.
Ratings data for REPL provided by MarketBeat
Replimune Group, Inc. (NASDAQ: REPL) had its price target raised by analysts at BMO Capital Markets from $14.00 to $18.00. They now have an "outperform" rating on the stock.
Ratings data for REPL provided by MarketBeat
Replimune Group, Inc. (NASDAQ: REPL) had its price target raised by analysts at Jefferies Financial Group Inc. from $16.00 to $19.00. They now have a "buy" rating on the stock.
Ratings data for REPL provided by MarketBeat
Replimune Group, Inc. (NASDAQ: REPL) had its price target raised by analysts at HC Wainwright from $17.00 to $21.00. They now have a "buy" rating on the stock.
Ratings data for REPL provided by MarketBeat
Replimune Group, Inc. (NASDAQ: REPL) had its price target raised by analysts at BMO Capital Markets from $18.00 to $27.00. They now have an "outperform" rating on the stock.
Ratings data for REPL provided by MarketBeat
Replimune Group, Inc. (NASDAQ: REPL) had its price target raised by analysts at HC Wainwright from $21.00 to $22.00. They now have a "buy" rating on the stock.
Ratings data for REPL provided by MarketBeat
Replimune Group, Inc. (NASDAQ: REPL) had its price target raised by analysts at JPMorgan Chase & Co. from $16.00 to $18.00. They now have an "overweight" rating on the stock.
Ratings data for REPL provided by MarketBeat
Replimune Group, Inc. (NASDAQ: REPL) had its price target raised by analysts at Piper Sandler from $14.00 to $22.00. They now have an "overweight" rating on the stock.
Ratings data for REPL provided by MarketBeat
Replimune Group, Inc. (NASDAQ: REPL) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating on the stock.
Ratings data for REPL provided by MarketBeat
Neueste Beiträge
B__Riley in WAVE Life Sciences Ltd diskutieren